Skip to content
Evigrade
CriticalProkinetic, 5-HT4 serotonin receptor agonist (withdrawn EU/US)×Systemic antimycotics. Imidazole derivatives

Updated · Methodology

Mechanism

Ketoconazole is a potent CYP3A4 inhibitor and can raise the levels of drugs that this enzyme metabolises (ketoconazole summary of product characteristics, SmPC, European Medicines Agency, EMA). According to the US ketoconazole label, oral ketoconazole potently inhibits the metabolism of cisapride and increases the area under the curve (AUC) of cisapride eight-fold on average. This can lead to serious cardiovascular events, including QT prolongation (ketoconazole label, US Food and Drug Administration, FDA). Ketoconazole itself may prolong the QT interval. In preclinical studies it inhibited the rapid cardiac delayed rectifier potassium current. Data from some clinical studies suggest that 200 mg twice daily for 3–7 days can increase the corrected QT interval (QTc) by a mean maximum of about 6–12 ms (ketoconazole FDA label). The EU ketoconazole SmPC does not mention cisapride. It states that interactions may be stronger at higher ketoconazole doses and shorter dosing intervals (ketoconazole SmPC, EMA).

Symptoms

Higher cisapride levels with ketoconazole can lead to serious cardiovascular events, including QT prolongation, which sometimes results in life-threatening ventricular arrhythmias such as torsade de pointes (ketoconazole label, US Food and Drug Administration, FDA). QT prolongation itself causes no symptoms and shows only on an electrocardiogram (ECG). A ventricular arrhythmia causes sudden strong palpitations, dizziness or fainting and can lead to cardiac arrest. The US ketoconazole label lists feeling faint, lightheaded or dizzy and an irregular or fast heartbeat as possible symptoms of QT prolongation (ketoconazole FDA label).

Management

The combination is contraindicated. The US labels for ketoconazole tablets name cisapride among contraindicated drugs in the boxed warning and in the Contraindications and Warnings sections. The interaction table says cisapride must not be given with ketoconazole under any circumstances and for up to one week after ketoconazole is stopped (ketoconazole labels, US Food and Drug Administration, FDA). The EU ketoconazole summary of product characteristics (SmPC) does not name cisapride, but states that its list of contraindicated combinations is not complete (ketoconazole SmPC, European Medicines Agency, EMA). Cisapride is not in the Spanish medicines register CIMA, so the ketoconazole documents set the level of risk. If a person takes cisapride obtained in another country, do not prescribe oral ketoconazole with it (ketoconazole FDA label). Ketoconazole is contraindicated in documented congenital or acquired prolongation of the corrected QT interval (QTc). Record an electrocardiogram (ECG) before treatment, within the first week and then as clinically indicated. The SmPC recommends ECG monitoring when a QTc-prolonging drug is given at the same time (ketoconazole SmPC, EMA). The contraindication applies to oral ketoconazole. In the European Union, ketoconazole tablets are used for endogenous Cushing's syndrome, and doctors experienced in endocrinology or internal medicine start and supervise treatment (ketoconazole SmPC, EMA). In adults, plasma ketoconazole was undetectable after the cream was applied to the skin or the gel to the scalp, but measurable after the gel was applied to the whole body. No interaction studies have been done with the cream or the gel (ketoconazole cream and gel SmPCs, Spanish Agency of Medicines and Medical Devices, AEMPS).

Your whole list in one report

Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email

Add more drugs

Medicine list: everything you take in one place →

Sources

Other interactions with Cisapride

Other interactions with Ketoconazole